The price has since fallen again and at the time of writing is trading at around the 110 level. Investor interest in 4D has been intense – we saw 4D share bid up from 36.25 on 15 July, to peak at 174 on 6 October. We also like biotech companies with a big library of patents and 4D has these in spades. For starters, 4D Pharma has been working with Merck for over two years, including on Keytruda, one of the biggest selling drugs in the world. It is well-positioned in the market for next generation research in an area of medicine that larger pharmaceutical companies are starting to take more seriously. The company is keen to emphasise that its work is not just about gut-related diseases, and that its work also covers oncology and immune system problems. LBPs could even provide breakthroughs for the treatment of asthma and other respiratory diseases. Brigadier Gold: results on exploratory drilling in Viva Zapata imminentĤD Pharma is also collaborating with Merck on vaccine research.We think this is a fast-evolving area of medicine with some very exciting implications for the treatment of auto-immune diseases and Parkinson’s, both of which continue to elude ready solutions. 4D Pharma: fast evolving area of medicine 4D Pharma works on solutions for diseases like cancer using proprietary technology that helps to identify live biotherapeutics. These are orally-delivered single strains of bacteria naturally found in the human gut. The NASDAQ listing would provide it with the capital needed to expand its research in the area of live biotherapeutic products (LBPs). It is obviously a positive move for the company and reflects confidence on the part of management and investors. “It is something we have worked on for a while.” “It is a big step for 4D Pharma it is a big step for any European biotech business to step across the Atlantic and become a US-listed business,” 4D Pharma CEO Duncan Peyton said in a call with Biopharma Reporter. 4D Pharma shares will continue to be available on AIM of course. The deal is still to be approved by the shareholders of 4D Pharma, so US investors are unlikely to see the stock until Q1 2021 at the earliest. 4D Pharma (LON:DDDD) says it is planning to move beyond its original AIM listing following its announced merger last month with Longevity, a NASDAQ-listed SPAC (Special Purpose Acquisition Company).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |